Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How is stomach damage minimized by rofecoxib's selective action?Can lipitor mitigate unhealthy fat impacts?How do patients report generic tigecycline's side effects vs name brand?Is there a specific date for apotex's ruxolitinib anda approval decision?Does azacitidine alter ruxolitinib's toxicity levels?
See the DrugPatentWatch profile for xiidra
Why is Xiidra experiencing a delay in generic entry? Xiidra, an eye drop medication used to treat dry eye disease, has a patent expiration date that is yet to be reached. However, due to the complications in the production and approval process of generic versions, its generic entry is expected to be delayed. What are the key reasons behind the delay in Xiidra's generic entry? According to [1] DrugPatentWatch.com, the patents for Xiidra have several layers of protection, including composition-of-matter patents, method-of-use patents, and use patents, which complicate the ability of generic manufacturers to enter the market. The patent holders, Shire Pharmaceutical (now known as Takeda Pharmaceutical) and Novartis (formerly the co-holder), have filed multiple lawsuits against generic companies attempting to bring generics to market. This has contributed to the delay in generic entry. When does exclusivity expire? The composition-of-matter and method-of-use patents related to Xiidra are expected to expire in 2028 [1], but it is uncertain if the generic version will enter the market as soon as these patents expire. The use patent related to Xiidra is set to expire in 2030 [1]. Can biosimilars enter before patent expiry? Biosimilars, which are highly similar but not identical versions of biologic drugs, have been gaining popularity. However, the development of a biosimilar version of Xiidra is still in its infancy, and it is uncertain if any biosimilars will be approved for generic entry before patent expiry. Timeline of patent expiry - Composition-of-matter and method-of-use patents expire in 2028 [1] - Use patent expires in 2030 [1] Competitors and alternative treatments Other treatments are available for treating dry eye disease, including Restasis (cyclosporine) and Cequa (cyclosporine). However, Xiidra has a distinct mechanism of action and is widely prescribed, making it an important treatment option for many patients. Patient concerns Patients using Xiidra may be concerned about the availability of the generic or biosimilar version of the medication. However, it is essential for patients to consult with their healthcare providers to ensure they receive the best possible treatment for their condition. Sources: [1] DrugPatentWatch.com (https://www.drugpatentwatch.com/patent/1451421)
Other Questions About Xiidra :